A systematic review on the role of bivalirudin in patients undergoing percutaneous coronary interventions: primus inter pares or a falling star?

ABSTRACT

Intracoronary thrombosis triggered by ruptured or eroded atherosclerotic plaques constitutes the predominant underlying cause of acute coronary syndromes (ACS). Thrombin is considered a central enzyme in hemostasis and thrombosis, and a well-established target for anticoagulant therapies. Bivalirudin was introduced in the clinical practice as a promising, reversible, direct thrombin inhibitor with a predictable anticoagulant effect. Initial randomized clinical trials demonstrated that bivalirudin compared with heparin on top of a glycoprotein IIb/IIIa inhibitor was associated with a significant reduction of major bleeding and favorable net clinical outcomes in patients undergoing percutaneous coronary interventions (PCI). The HORIZON-AMI trial even indicated mortality benefit in bivalirudin-treated patients. Thereby, the 2011 and 2012 European Society of Cardiology Guidelines on the management of non-ST-segment elevation ACS and ST-segment elevation myocardial infarction positioned bivalirudin as the anticoagulant of choice in the PCI setting. Further randomized studies, better reflecting routine clinical practice, revealed significantly increased rates of stent thrombosis and myocardial infarction in the bivalirudin arm. Additionally, these findings were corroborated in the subsequent meta-analyses. Speculations that excessive occurrence of stent thrombosis and myocardial infarction may be caused by too short duration of post PCI bivalirudin infusion did not find confirmation in the latest MATRIX trial. In this systematic review, we aim to assess the efficacy and safety of bivalirudin therapy in patients undergoing PCI and to formulate recommendations on the bivalirudin use for clinicians. In our opinion, the research evidence and pharmacoeconomic considerations strongly support the use of bivalirudin in PCI patients at high risk of bleeding complications, while in other situations old and inexpensive UFH or enoxaparin remain the first line antithrombotic drugs.

Key words: bivalirudin, thrombin, antithrombotic treatment, acute coronary syndrome, percutaneous coronary intervention

Introduction

Coronary artery disease (CAD) remains the leading cause of death worldwide. All over the world over seven millions of people die from CAD annually, which accounts for 13.1% of all deaths [1]. In Europe, every sixth man and every seventh woman is expected to die from myocardial infarction (MI) [2]. The mainstay of treatment in patients with acute coronary syndromes (ACS) includes intensive antithrombotic and anti-ischemic therapy together with invasive coronary procedures. Primary percutaneous coronary
intervention (PCI), when compared with thrombolytic therapy, was demonstrated to reduce all-cause mortality as well as re-MI and stroke rates in patients with ST-segment elevation myocardial infarction (STEMI) and therefore, is considered the preferred reperfusion strategy in this setting (class of indication I, level of evidence A) [2]. Additionally, currently the majority of subjects with non-ST-segment elevation ACS also undergo PCI procedures. In this setting, interventional treatment, when compared with conservative strategy, prevents recurrent episodes of coronary ischemia and in intermediate- to high-risk patients is associated with improved survival and lower risk of MI. PCI procedures effectively restore patency of culprit coronary arteries and improve myocardial perfusion [3]. Importantly, PCI interventions are performed in a highly thrombogenic environment. Intracoronary thrombosis triggered by ruptured or eroded atherosclerotic plaques constitutes the predominant underlying cause of ACS events. Exposure of subendothelial proteins to the flowing blood at sites of plaque disruption leads to platelets activation and aggregation as well as to the release of vasoactive and procoagulant mediators. In details, tissue factor (TF) originating from the unstable coronary plaques induces thrombin generation, which may result in the formation of a platelet- and fibrin-rich intracoronary thrombus. Thrombin is considered a central enzyme in hemostasis and thrombosis, and a well-established target for anticoagulant therapies (Fig. 1) [4]. Anticoagulant regimens utilized during PCI procedures include: unfractionated heparin (UFH), low molecular weight heparins, particularly enoxaparin and bivalirudin [2, 5–9]. Recently, numerous randomized trials on the role of bivalirudin in patients undergoing PCI have been published. Their inconsistent results, arising from the important differences in study designs and changes in interventional practice, have fueled an ongoing debate on bivalirudin in the cardiological community. Therefore, we aim to conduct a systematic review in order to assess the efficacy and safety of bivalirudin therapy in patients undergoing PCI and to formulate recommendations on the bivalirudin use for clinicians.

**Search strategy**

A systematic investigation of all published and unpublished literature, including oral presentations, was conducted to minimize the risk of bias. Briefly, we followed the PRISMA statement for reporting systematic reviews in health care interventions [10]. A database search including PubMed and Google Scholar databases, without time limitations, was conducted on 3rd September 2015 by two independent investigators (K.O. and M.K.). Proceedings from the Scientific Sessions of the American College of Cardiology (http://www.acc.org), American Heart Association (http://www.heart.org), European Society of Cardiology (http://www.escardio.org) were also considered. The following key words were applied: “bivalirudin”, “hirulog”, “bivalirudin” and “percutaneous coronary intervention”, and “hirulog” and “percutaneous coronary intervention”. References of the retrieved studies were searched manually for additional studies and reviews. No language restrictions were applied. Data were abstracted on prespecified forms. All divergences were resolved by discussion with a third investigator (JK). Reviews were also considered a source of citations of the relevant studies and interpretation of their results.

After a systematic search 24,343 citations were identified: 2,661 in PubMed, 17,840 in Google Scholar, and 3,842 in other databases. Duplicate / multiple citations and reviews not containing any relevant information were excluded. Eventually, 44 original reports and

---

**Figure 1.** Target of bivalirudin in the coagulation cascade; V, VII, VIII, IX, X, XI, XII, XIII — coagulation factors; a — active form; Ca^{2+} — calcium ions; PL — platelet membrane phospholipids; TF — tissue factor
Chemical structure of bivalirudin (C_{98}H_{138}N_{24}O_{33})

Interactions between bivalirudin and thrombin. Bivalirudin binds to both active site and exosite 1. Bivalirudin inhibits both fibrin-bound and soluble thrombin. Cleaved bivalirudin can be displaced by competitive substrates; A — active site (catalytic site responsible for enzymatic actions of thrombin); E1 — exosite 1 (substrate recognition and fibrinogen-binding site); E2 — exosite 2 (heparin-binding site)

Pharmacological properties of bivalirudin

Bivalirudin, a synthetic analog of the carboxy terminus of hirudin, is a reversible, direct thrombin inhibitor (Fig. 2). It exerts a predictable anticoagulant effect, since it does not bind to plasma proteins. Notably, bivalirudin does not require antithrombin for its anticoagulant action and inhibits both fibrin-bound and soluble thrombin (Fig. 3). Additionally, bivalirudin binds to both active site and exosite 1 of thrombin, thereby competing with exosite 1 for fibrin binding and enhancing displacement of thrombin from fibrin. Following its binding to bivalirudin, thrombin cleaves the Pro-Arg bond within the amino terminal of bivalirudin allowing the recovery of thrombin activity. Bivalirudin has a plasma half-life of 25 minutes after its intravenous administration and only 20% of the given dose is cleared through kidneys [3, 11–13]. According to the experiments performed by Butenas et al. [14], increasing concentrations of bivalirudin prolong the initiation phase of thrombin generation in a concentration-dependent manner. Interestingly, the investigators demonstrated an increased thrombin generation at subpharmacologic concentrations of bivalirudin (0.5–2.0 µmol/L), however, at a pharmacologic concentration (5.0 µmol/L) bivalirudin effectively suppressed thrombin generation and inhibited platelet activation by around 80%. These observations led to the conclusion that bivalirudin acts not as a modulator but as an ‘on-off’ switch of blood coagulation [14]. Tanaka et al. demonstrated substantial differences between heparin and bivalirudin in terms of the kinetics of thrombus formation [15]. In the blood samples collected from 12 healthy volunteers, the authors found that increasing concentrations of bivalirudin and heparin progressively delayed the onset of thrombin formation, but only heparin dose-dependently decreased the amount of gener-
Results of initial randomized clinical trials: a rising star...

After initial randomized clinical trials were published, this hope became more realistic. In details, the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) investigators randomly assigned 13,819 moderate or high risk ACS patients undergoing invasive management to one of three antithrombotic regimens: UFH or enoxaparin plus a glycoprotein IIb/IIIa inhibitor, bivalirudin plus a glycoprotein IIb/IIIa inhibitor, or bivalirudin with bailout use of a glycoprotein IIb/IIIa inhibitor [20]. The use of bivalirudin plus a glycoprotein IIb/IIIa inhibitor, as compared with UFH or enoxaparin plus a glycoprotein IIb/IIIa inhibitor, was associated with similar 30-day rates of the composite ischemia end point (death, MI, or unplanned coronary revascularization for ischemia: 7.7% v. 7.3%; relative risk [RR] 1.07; 95% confidence interval [CI] 0.92–1.23; p = 0.39), major bleeding (5.3% v. 5.7%; RR 0.93; 95% CI 0.78–1.10; p = 0.38), and the net clinical outcome end point (composite of the ischemia end point and major bleeding: 11.8% v. 11.7%; RR 1.01; 95% CI 0.90–1.12; p = 0.93). Similarly, when bivalirudin was used alone, as compared with UFH or enoxaparin plus a glycoprotein IIb/IIIa inhibitor, there was no difference in the rate of composite ischemia end point (7.8% v. 7.3%; RR 1.08; 95% CI 0.93–1.24; p = 0.32), but the rates of major bleeding (3.0% v. 5.7%; RR 0.53; 95% CI 0.43–0.65; p < 0.001) and net clinical outcome end point (10.1% v. 11.7%; RR 0.86; 95% CI 0.77–0.97; p = 0.02) were significantly reduced. Additionally, at 1 year, no statistically significant differences in the rates of composite ischemia end point or mortality with the 3 compared therapies were found [21].

The most favorable results for bivalirudin among all so far conducted randomized clinical studies were achieved in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial [22]. This study included 3,602 STEMI patients undergoing primary PCI. The investigators demonstrated that anticoagulation with bivalirudin alone, as compared with UFH plus a glycoprotein IIb/IIIa inhibitor, resulted in a reduced 30-day rate of net adverse clinical events, defined as the combination of major bleeding or major adverse cardiovascular events, including death, reinfection, target-vessel revascularization for ischemia and stroke (9.2% v. 12.1%; RR 0.76; 95% CI 0.63–0.92; p = 0.005), owing to a lower rate of major bleeding (4.9% v. 8.3%; RR 0.60; 95% CI 0.46–0.77; p < 0.001). Importantly, treatment with bivalirudin alone, as compared with UFH plus a glycoprotein IIb/IIIa inhibitor, resulted in significantly lower 30-day rates of death from cardiac causes (1.8% v. 2.9%; RR 0.62; 95% CI 0.40–0.95; p = 0.03) and death from all causes (2.1% v. 3.1%; RR 0.66; 95% CI 0.44–1.00; p = 0.047). Unfortunately, there was an increased risk of acute stent thrombosis (within 24 h) in the bivalirudin group (1.3% v. 0.3%; p < 0.001), but no significant increase was present by 30 days (2.5% v. 1.9%; p = 0.30). At 3-year follow-up, the superiority of bivalirudin monotherapy over the combination of UFH and a glycoprotein IIb/IIIa inhibitor became even more evident. Compared with 1,802 patients allocated to receive UFH plus a glycoprotein IIb/IIIa inhibitor, 1,800 patients allocated to bivalirudin monotherapy had lower rates of all-cause mortality (5.9% v. 7.7%; hazard ratio [HR] 0.75; 95% CI 0.58–0.97; p = 0.03), cardiac mortality (2.9% v. 5.1%; HR 0.56; 95% CI 0.40–0.80; p = 0.001), re-MI (6.2% v. 8.2%; HR 0.76; 95% CI 0.59–0.99; p = 0.04), and major bleeding not related to bypass graft surgery (6.9% v. 10.5%; HR 0.64; 95% CI 0.51–0.80; p = 0.0001), with no significant differences in ischemia-driven target vessel revascularization, stent thrombosis, or composite adverse events [23].

Another large study, the EUROMAX (European Ambulance Acute Coronary Syndrome Angiography) trial, tested in 2,218 STEMI patients whether prehospital...
administration of bivalirudin continued for 4 hours after primary PCI improves clinical outcomes compared with the guideline-recommended UFH or enoxaparin [24]. The investigators revealed that bivalirudin, as compared with the control intervention, reduced the risk of the primary outcome, which was a composite of death or major bleeding not associated with coronary artery bypass grafting (CABG) at 30 days, (5.1% v. 8.5%; RR 0.60; 95% CI 0.43–0.82; p = 0.001) and the principal secondary outcome, defined as a composite of death, re-MI, or non-CABG major bleeding (6.6% v. 9.2%; RR 0.72; 95% CI 0.54–0.96; p = 0.02). Bivalirudin also reduced the risk of major bleeding (2.6% v. 6.0%; RR 0.43; 95% CI 0.28–0.66; p < 0.001). Similarly to the previously discussed study, the risk of acute stent thrombosis was higher with bivalirudin (1.1% v. 0.2%; RR 6.11; 95% CI 1.37–27.24; p = 0.007). There was no significant difference in rates of death (2.9% v. 3.1%) or re-MI (1.7% v. 0.9%) [25].

Based on the results of the above discussed randomized clinical trials, the 2011 and 2012 European Society of Cardiology Guidelines on the management of non-ST-segment elevation ACS and STEMI positioned bivalirudin as the anticoagulant of choice in the PCI setting (Tab. 1).

Black clouds over bivalirudin according to the recent trials

A recently published open-label, single centre, randomized HEAT-PPCI (How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention) trial comparing bivalirudin v. UFH alone in the STEMI setting unexpectedly revealed an excess of cardiac ischemic events (the primary efficacy outcome — a composite of all-cause mortality, cerebrovascular accident, re-MI, or unplanned target lesion revascularization: 8.7% v. 5.7%; RR 1.52; 95% CI 1.09–2.13; p = 0.01) associated with bivalirudin therapy, which was predominantly driven by the significantly increased rate of MI in the bivalirudin group (2.7% v. 0.9%; RR 3.01; 95% CI 1.36–6.66; p = 0.004), and no difference in major bleeding events between both study arms (type 3–5 bleedings according to the Bleeding Academic Research Consortium classification: 3.5% v. 3.1%; RR 1.15; 95% CI 0.70–1.89; p = 0.59) [26].

These data suggest that the inconsistency between the results of the HEAT-PPCI trial and the previously conducted studies may be driven by the concomitant administration of a glycoprotein IIb/IIIa inhibitor in heparin-treated patients. A recently published meta-analysis of 13 randomized studies including 24,605 patients showed that the incidence of 30-day all-cause death as well as 30-day MI did not differ significantly between the bivalirudin and UFH groups, independently of the concomitant use of a glycoprotein IIb/IIIa inhibitor [20, 22, 26–39]. The rate of 30-day major bleeding events was significantly lower in bivalirudin-treated patients as compared with those receiving UFH with the routine use of a glycoprotein IIb/IIIa inhibitor (odds ratio [OR] 0.52; 95% CI 0.45–0.60; p < 0.001), but not if compared with the UFH plus provisional administration of a glycoprotein IIb/IIIa inhibitor group (OR 0.66, 95% CI 0.33–1.32; p = 0.24). The overall rate of 30-day definite stent thrombosis increased significantly with bivalirudin as compared with coadministration of UFH and a glycoprotein IIb/IIIa inhibitor (OR 1.67; 95% CI 1.13–2.45; p = 0.01). The prevalence of stent thrombosis was also numerically greater with bivalirudin as compared with heparin plus provisionally administered glycoprotein IIb/IIIa inhibitor. However, the difference did not reach statistical significance (OR 2.08; 95% CI 0.35–12.32; p = 0.42). Bivalirudin treatment was associated with a significant increase in the Odds of acute stent thrombosis (> 24h–30 days), when compared with heparin administration (acute stent thrombosis: OR 4.49; 95% CI 2.42–8.36; p < 0.001; subacute stent thrombosis: OR 1.10; 95% CI 0.62–1.97; p = 0.74). The magnitude and direction of the estimates were consistent independently from the use of a glycoprotein IIb/IIIa inhibitor in UFH-treated patients. The overall effect of the treatment, however, is reflected by the net adverse clinical events (NACE) rate, defined as a composite of ischemic events (death, MI, repeat revascularization, along with ST and stroke) and major bleeding. There were significantly fewer NACE with bivalirudin compared with UFH plus the routine use of a glycoprotein IIb/IIIa inhibitor (OR 0.77; 95% CI 0.65–0.91; p = 0.002). A numerical reduction in the odds of NACE in bivalirudin-treated patients was not-significant as compared with UFH without the routine use of a glycoprotein IIb/IIIa inhibitor (OR 0.76; 95% CI 0.51–1.13; p = 0.18) [39]. Another recent meta-analysis by Kianoush et al. including 41,243 patients from 25 randomized trials, demonstrated that the use of bivalirudin compared with active control was associated with an increased risk of definite stent thrombosis (RR 1.73; 95% CI 1.24–2.40; p < 0.001; number needed to harm [NNH] 182), similar risk of MI (RR 1.00; 95% CI 0.87–1.16; p = 0.96), decreased risk of major bleeding (RR 0.59; 95% CI 0.49–0.72; p < 0.001; number needed to treat [NNT] 79) and of cardiac death (RR 0.72; 95% CI 0.53–0.99; p = 0.05), but no effect on all-cause mortality (RR 0.96; 95% CI 0.81–1.15; p = 0.69) [40].

All available research evidence consistently shows that therapy with bivalirudin in ACS patients is associated with a significant reduction of major bleeding when compared with the regimen including UFH and
Table 1. Recommendations of the European Society of Cardiology on the anticoagulation in patients undergoing PCI, with a particular emphasis on the use of bivalirudin

<table>
<thead>
<tr>
<th>CAD setting</th>
<th>Recommendation</th>
<th>Class of recommendation</th>
<th>Level of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>2011 ESC Guidelines on NSTE-ACS [5]</td>
<td>Bivalirudin plus provisional GP IIb/IIIa receptor inhibitors are recommended as an alternative to UFH plus GP IIb/IIIa receptor inhibitors in patients with an intended urgent or early invasive strategy, particularly in patients with high risk of bleeding</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>NSTE-ACS</td>
<td>Bivalirudin (with use of GP IIb/IIIa blocker restricted to bailout) is recommended over UFH and a GP IIb/IIIa blocker</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>2012 ESC Guidelines on STEMI [2]</td>
<td>Bivalirudin (with or without routine GP IIb/IIIa blocker) may be preferred over unfractionated heparin</td>
<td>Iib</td>
<td>B</td>
</tr>
<tr>
<td>STEMI</td>
<td>Unfractionated heparin with or without routine GP IIb/IIIa blocker must be used in patients not receiving bivalirudin, or enoxaparin</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>2014 ESC Guidelines on myocardial revascularization [6]</td>
<td>Bivalirudin 0.75 mg/kg i.v. bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) is recommended as alternative to UFH plus GP IIb/IIIa receptor inhibitor during PCI</td>
<td>IIa</td>
<td>A</td>
</tr>
<tr>
<td>SCAD</td>
<td>UFH 70–100 U/kg</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>NSTE-ACS</td>
<td>UFH 70–100 IU/kg (50–70 IU/kg if concomitant with GPIIb/IIIa inhibitors) is recommended in patients undergoing PCI who did not receive any anticoagulant</td>
<td>I</td>
<td>B</td>
</tr>
<tr>
<td>2015 ESC Guidelines on NSTE-ACS [7]</td>
<td>Bivalirudin should be considered as anticoagulant for PCI if patients cannot receive bivalirudin</td>
<td>Ila</td>
<td>B</td>
</tr>
<tr>
<td>NSTEMI</td>
<td>The anticoagulation is selected according to both ischemic and bleeding risks, and according to the efficacy-safety profile of the chosen agent</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>NSTE-ACS</td>
<td>The anticoagulation is selected according to both ischemic and bleeding risks, and according to the efficacy-safety profile of the chosen agent</td>
<td>I</td>
<td>C</td>
</tr>
<tr>
<td>Bivalirudin (0.75 mg/kg bolus, followed by 1.75 mg/kg/h for up to 4 h after the procedure) is recommended as alternative to UFH plus GP IIb/IIIa receptor inhibitor during PCI</td>
<td>I</td>
<td>A</td>
<td></td>
</tr>
<tr>
<td>UFH is recommended as anticoagulant for PCI if patients cannot receive bivalirudin</td>
<td>I</td>
<td>C</td>
<td></td>
</tr>
</tbody>
</table>

CAD — coronary artery disease; ECS — European Society of Cardiology; GP — glycoprotein; NSTE-ACS — non-ST-segment elevation acute coronary syndrome; PCI — percutaneous coronary intervention; SCAD — stable coronary artery disease; STEMI — ST-segment elevation myocardial infarction; UFH — unfractionated heparin
a glycoprotein IIb/IIIa inhibitor. Bivalirudin also poses an increased risk of acute stent thrombosis when compared with heparin routinely or provisionally coadministered with a glycoprotein IIb/IIIa inhibitor. These facts together with a short half-life of bivalirudin (around 25 min) led to the formulation of the hypothesis that excessive rates of stent thrombosis and MI observed in bivalirudin-treated patients may be related to the short duration of bivalirudin infusion and/or the timing and potency of the administered antplatelet agents [41]. This hypothesis was initially supported by a study published by Cortese et al. [42]. The authors compared the effects of bivalirudin given as a bolus followed by 4-hour infusion v. bivalirudin given as a bolus followed by peri-PCI infusion v. a bolus of UFH on top of abciximab. The study population consisted of 264 STEMI patients undergoing primary PCI who were pretreated with aspirin and clopidogrel. The primary study end point, defined as > 70% ST-segment resolution within 90 minutes after PCI, was achieved in 69.8%, 48.8%, and 69.6% of patients, respectively (p = 0.048 for the comparison between the prolonged and standard bivalirudin infusion groups, p = 0.98 for the comparison between the prolonged bivalirudin infusion and UFH plus abciximab groups). Major bleedings were not significantly different among the study arms. The encouraging results suggested that the strategy of prolonged bivalirudin infusion after primary PCI, but not peri-PCI bivalirudin infusion, may be equivalent to the strategy with UFH plus abciximab in the STEMI setting [42].

However, this enthusiasm was tempered by the recently published findings of the MATRIX (Minimizing Adverse Haemorrhagic Events by TRansradial Access Site and Systemic Implementation of angioX) trial [43]. The investigators randomly assigned 7,213 ACS patients for whom PCI was anticipated to receive either bivalirudin or UFH. Patients in the bivalirudin group were subsequently randomly assigned to receive or not to receive a post-PCI bivalirudin infusion. Primary outcomes for the comparison between bivalirudin and heparin were the occurrence of major adverse cardiovascular events (a composite of death, myocardial infarction, or stroke) and net adverse clinical events (a composite of major bleeding or a major adverse cardiovascular event). Clinical follow-up was performed at 30 days. The primary outcome for the comparison of a post-PCI bivalirudin infusion with no post-PCI infusion was a composite of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events. Bivalirudin failed to reduce the rates of both major adverse cardiovascular events (10.3% v. 10.9%; RR 0.94; 95% CI 0.81–1.09; p = 0.44) and net adverse clinical events (11.2% v. 12.4%; RR 0.89; 95% CI 0.78–1.03; p = 0.12) as compared with UFH. Moreover, post-PCI bivalirudin infusion, as compared with no infusion, did not significantly decrease the rate of urgent target-vessel revascularization, definite stent thrombosis, or net adverse clinical events (11.0% v. 11.9%; RR 0.91; 95% CI 0.74–1.11; p = 0.34). In this study, there was no significant difference in the rate of definite or probable stent thrombosis between the groups (1.3% v. 1.0%; RR 1.28; 95% CI 0.82–2.00; p = 0.27), although the rate of definite stent thrombosis was higher in the bivalirudin group (1.0% v. 0.6%; RR 1.71; 95% CI 1.00–2.93; p = 0.048). Contrary to the expectations, post-PCI infusion of bivalirudin, as compared with no post-PCI infusion, did not lower the rate of definite stent thrombosis (1.3% v. 0.7%; RR 1.78; 95% CI 0.90–3.53; p = 0.09) [43]. Consistently with some of the previous reports [22, 25], the MATRIX investigators found a lower rate of major bleeding (1.7% v. 2.3%; RR 0.71; 95% CI 0.51–0.99; p = 0.04) and lower all-cause mortality (1.4% v. 2.5%; RR 0.55; 95% CI 0.39–0.78; p < 0.001) in bivalirudin v. UFH-treated patients [43]. Interestingly, the authors raised the issue of the differences in definitions of individual elements of composite outcomes in other studies which might have influenced the interpretation of their results. However, the definition of re-MI used in the MATRIX study was in agreement with the third universal definition of myocardial infarction.

In general, the results of the recently published randomized studies are much less favorable for bivalirudin than the initial ones (Tab. 2) [20–45]. This fact is reflected in the latest guidelines of the European Society of Cardiology where the role of bivalirudin in patients undergoing PCI was considerably downgraded (Tab. 1). The discrepancy in the trial results may be multicausal. First of all, some of the landmark studies (e.g. the HORIZONS-AMI trial) were suboptimally designed, favoring bivalirudin. The bleeding benefit identified in the older studies seems to be caused rather by a higher bleeding incidence in the comparator arm due to the disproportional use of a glycoprotein IIb/IIIa inhibitor with heparin than beneficial properties of bivalirudin. Additionally, recent changes in interventional practice, such as increasing use of radial access, lower doses of UFH, decreased use of glycoprotein IIb/IIIa inhibitors and administration of more effective platelet P2Y12 receptor inhibitors, are suggested to diminish the benefits of bivalirudin v. UFH therapy. Although bivalirudin is currently reimbursed in the majority of European countries, including Poland, pharmacoeconomic considerations clearly favor UFH or enoxaparin over bivalirudin in the PCI setting.
<table>
<thead>
<tr>
<th>Study and year</th>
<th>CAD setting</th>
<th>Randomization</th>
<th>Number of patients</th>
<th>Time of bivalirudin infusion [h]</th>
<th>Primary outcome</th>
<th>All-cause death</th>
<th>TIMI major bleeding</th>
<th>Definite stent thrombosis</th>
<th>Net adverse clinical events</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>REPLACE 2 [36]</strong> 2003</td>
<td>ACS/stable angina</td>
<td>Bivalirudin/UFH + GPI</td>
<td>6010</td>
<td>PCI duration</td>
<td>Net adverse clinical events: death, MI, urgent repeat revascularization, in-hospital major bleeding</td>
<td>9.2 10.0 0.92 (0.79-1.08)</td>
<td>0.2 0.4 0.59 (0.23-1.49)</td>
<td>0.6 0.9 0.73 (0.41-1.32)</td>
<td>NR NR NR</td>
</tr>
<tr>
<td><strong>ACUITY [20]</strong> 2006</td>
<td>NSTE-ACS</td>
<td>Bivalirudin/Bivalirudin + GPI/UFH or enoxaparin + GPI</td>
<td>13819</td>
<td>PCI duration</td>
<td>Composite ischemia end point: death, MI, unplanned revascularization for ischemia</td>
<td>7.7 7.3 1.07 (0.95-1.31)</td>
<td>^1.5 1.3 1.13 (0.80-1.58)</td>
<td>^1.7 1.9 0.50 (0.35-0.72)</td>
<td>NR NR NR</td>
</tr>
<tr>
<td><strong>HORIZONS-AMI [22]</strong> 2008</td>
<td>STEMI</td>
<td>Bivalirudin/UFH</td>
<td>3602</td>
<td>PCI duration</td>
<td>Net adverse clinical events: death, MI, urgent target vessel revascularization or major bleeding</td>
<td>9.2 12.1 0.76 (0.69-0.90)</td>
<td>2.1 3.1 0.66 (0.44-1.00)</td>
<td>3.1 5.0 0.61 (0.44-0.84)</td>
<td>2.2 1.4 1.59 (0.94-2.70)</td>
</tr>
<tr>
<td><strong>ISAR-REACT3 [32]</strong> 2008</td>
<td>UA/stable angina</td>
<td>Bivalirudin/UFH</td>
<td>4570</td>
<td>PCI duration</td>
<td>Net adverse clinical events: death, MI, urgent target vessel revascularization or major bleeding</td>
<td>8.3 8.7 0.94 (0.77-1.15)</td>
<td>0.1 0.2 0.75 (0.17-3.34)</td>
<td>0.5 1.1 0.50 (0.25-0.99)</td>
<td>0.5 0.4 1.33 (0.56-3.15)</td>
</tr>
<tr>
<td><strong>ISAR-REACT 4 [33]</strong> 2011</td>
<td>STEMI</td>
<td>Bivalirudin/UFH + GPI</td>
<td>1721</td>
<td>PCI duration</td>
<td>Net adverse clinical events: death, large recurrent MI, urgent target vessel revascularization or major bleeding</td>
<td>11.0 10.9 1.01 (0.77-1.32)</td>
<td>1.6 1.4 1.17 (0.54-2.51)</td>
<td>1.9 2.2 0.84 (0.44-1.63)</td>
<td>0.7 0.6 1.20 (0.37-3.92)</td>
</tr>
<tr>
<td><strong>ARMADA-7-BIVALVE [50]</strong> 2012</td>
<td>NSTE-ACS/stable angina</td>
<td>Bivalirudin/UFH</td>
<td>401</td>
<td>PCI duration</td>
<td>Primary efficacy end point: cardiac death, MI, ST, TVR</td>
<td>11.1 8.9 1.25 (0.69-2.26)</td>
<td>0.5 0.0 3.08 (0.13-7.56)</td>
<td>0.5 1.0 0.51 (0.06-5.61)</td>
<td>0.5 0.0 3.08 (0.13-7.56)</td>
</tr>
<tr>
<td><strong>EUROMAX [25,45]</strong> 2013</td>
<td>STEMI</td>
<td>Bivalirudin or enoxaparin</td>
<td>2198</td>
<td>4</td>
<td>Death or major bleeding not associated with CABG</td>
<td>5.1 8.5 0.60 (0.43-0.82)</td>
<td>2.9 3.1 0.96 (0.60-1.54)</td>
<td>1.3 2.1 0.62 (0.32-1.23)</td>
<td>1.6 0.5 2.89 (1.14-7.29)</td>
</tr>
<tr>
<td><strong>BRAVE-4 [30]</strong> 2014</td>
<td>STEMI</td>
<td>Bivalirudin + prasugrel/UFH or clopidogrel</td>
<td>548</td>
<td>PCI duration</td>
<td>Primary composite end point: death, MI, unplanned revascularization in infantar related artery, ST, stroke, major bleeding</td>
<td>15.6 14.5 1.09 (0.0-1.79)</td>
<td>2.6 2.5 1.02 (0.31-3.37)</td>
<td>2.6 2.9 0.89 (0.28-2.78)</td>
<td>1.1 1.5 0.77 (0.11-4.49)</td>
</tr>
<tr>
<td><strong>HEAT-PPCI [26]</strong> 2014</td>
<td>STEMI</td>
<td>Bivalirudin</td>
<td>1812</td>
<td>PCI duration</td>
<td>Primary efficacy end point: all-cause mortality, cerebrovascular accident, reinfarction, unplanned target lesion revascularization</td>
<td>8.7 5.7 1.52 (1.09-2.13)</td>
<td>5.1 4.3 1.18 (0.78-1.79)</td>
<td>3.5* 3.1* (0.70-1.89)</td>
<td>3.3 0.7 4.50 (1.72-11.77)</td>
</tr>
</tbody>
</table>

Table 2. Overview of 30-day outcomes of the major randomized trials on bivalirudin in patients undergoing PCI.
Conclusions

In our opinion, the research evidence and pharmacoeconomic considerations presented above strongly support the use of bivalirudin in PCI patients at high risk of bleeding complications, while in other situations old and inexpensive UFH or enoxaparin remain the first line antithrombotic drugs.

Conflict of interest

Prof. Grzegorz Grzešk received honoraria for the lectures from The Medicines Company, the manufacturer of bivalirudin. All other authors have reported that they have no relevant competing interests to disclose.

References


